A week later, Abraham woke up in the middle of the night and tried to stand. She collapsed to the floor, struggling to ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

SAN DIEGO -- A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III ...

Former Beltrami jail nurse Michelle Skroch made her first appearance in court Friday. She’s charged with criminal neglect and ...

This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), ...

Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting ...

Sadly, his career was cut short due to an autoimmune disorder, Guillain-Barre syndrome. He sat out the entire 2018 campaign before returning in 2019. While he played well, he didn’t believe he ...